All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Shares in Repros Therapeutics Inc. spiked Friday on news that the FDA had cleared the company to perform a new study of Proellex, lifting a long-standing clinical hold that had been placed on its drug candidate for uterine fibroids and endometriosis. (BioWorld Today)